AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15509084 — intervention group
Group type: COMPARATOR
Intervention: DCPD toothpaste (dicalcium phosphate dihydrate)
Number of subjects: 600
Study 15509084 — intervention group
Group type: COMPARATOR
Intervention: PCC toothpaste (precipitated calcium carbonate)
Number of subjects: 600
Study 11567200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot group (promotion programmes)
Number of subjects: 7382
Study 11567200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no promotion programmes)
Number of subjects: 7382
Study 11567200 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 7382
Study 9624074 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 241
Study 9624074 — intervention group
Group type: COMPARATOR
Intervention: Acute hospital care
Number of subjects: 241
Study 7883291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treated group (Gp B) - 45 mg elemental zinc, single daily post lunch dose
Number of subjects: 162
Study 7883291 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Gp A)
Number of subjects: 162
Study 7883291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc treated group (Gp B)
Number of subjects: 162
Study 3123538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium therapy (active)
Number of subjects: 29
Study 3123538 — intervention group
Group type: COMPARATOR
Intervention: Placebo theophylline (control)
Number of subjects: 29
Study 3123538 — intervention group
Group type: COMPARATOR
Intervention: Theophylline therapy (prior treatment)
Number of subjects: 29
Study 30212848 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-player exergames
Number of subjects: 72
Study 30212848 — intervention group
Group type: COMPARATOR
Intervention: Single-player exergames
Number of subjects: 72
Study 27057600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) program, 24 weeks, 3 times per week
Number of subjects: 113
Study 27057600 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 113
Study 25287282 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise twice a week during gestational weeks 14‐25
Number of subjects: 92
Study 25287282 — intervention group
Group type: COMPARATOR
Intervention: Generalized exercise recommendation, home‐based training program, and telephone follow up
Number of subjects: 92
Study 23903454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound edge protection device
Number of subjects: 760
Study 23903454 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 760
Study 21784350 — intervention group
Group type: EXPERIMENTAL
Intervention: Semagacestat (γ‐secretase inhibitor)
Number of subjects: 2762
Study 21784350 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanezumab (anti-Aβ monoclonal antibody)
Number of subjects: 2762
Study 21784350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2762
Study 19493297 — intervention group
Group type: EXPERIMENTAL
Intervention: IST(R) appliance
Number of subjects: 103
Study 19493297 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP() appliance
Number of subjects: 103
Study 19493297 — intervention group
Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 103
Study 16676776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 38
Study 16676776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15294387 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback condition
Number of subjects: 0
Study 15294387 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback condition
Number of subjects: 0
Study 15294387 — intervention group
Group type: COMPARATOR
Intervention: Control group (yoked control partner)
Number of subjects: 0
Study 11375848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g IV)
Number of subjects: 164
Study 7488285 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus cyclophosphamide (intravenous bolus)
Number of subjects: 62
Study 7488285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges
Number of subjects: 62
Study 2096413 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms selenium daily for 5 weeks
Number of subjects: 50
Study 2096413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 356311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 46
Study 356311 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 46
Study 31482307 — intervention group
Group type: EXPERIMENTAL
Intervention: L19IL2 in combination with dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 69
Study 31482307 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 69
Study 27575306 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective EVAR
Number of subjects: 1231
Study 27575306 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1231
Study 26161612 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-Ketamine (MK)
Number of subjects: 13
Study 26161612 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (M)
Number of subjects: 13
Study 25384996 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-gated strategy with 4-dimensional CT treatment planning
Number of subjects: 14
Study 25384996 — intervention group
Group type: COMPARATOR
Intervention: Ungated strategy with 1× PCR
Number of subjects: 14
Study 25384996 — intervention group
Group type: COMPARATOR
Intervention: Ungated strategy with 4× PCR
Number of subjects: 14
Study 24654220 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid dose
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Average pain intensity
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Pain right now
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Worst pain intensity
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Pain at its least
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Pain relief
Number of subjects: 2201
Study 24654220 — intervention group
Group type: COMPARATOR
Intervention: Pain interference
Number of subjects: 2201
Study 19858764 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 2380
Study 19858764 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + progestin therapy
Number of subjects: 2380
Study 19858764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2380
Study 17345052 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (maximum 100 units)
Number of subjects: 40
Study 17345052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 16262020 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg 3 times daily for 7 days) and cephalexin (500 mg twice daily for 5 days)
Number of subjects: 224
Study 16262020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antimicrobials)
Number of subjects: 224
Study 16262020 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and cephalexin
Number of subjects: 224
Study 16262020 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted mothers (<25th centile or 146.4 cm)
Number of subjects: 224
Study 16262020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal body mass index (<25th centile or 18)
Number of subjects: 224
Study 16262020 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (>75th centile or 21.2)
Number of subjects: 224
Study 11923647 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 8
Study 11923647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10221237 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C and 800 mg vitamin E (n = 15)
Number of subjects: 31
Study 10221237 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo capsules (n = 16)
Number of subjects: 31
Study 10221237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged abstinence time
Number of subjects: 31
Study 8549178 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld portable spirometer
Number of subjects: 75
Study 8549178 — intervention group
Group type: COMPARATOR
Intervention: Conventional volume displacement spirometer
Number of subjects: 75
Study 1702048 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucagon (treatment group)
Number of subjects: 38
Study 1702048 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 38
Study 6342955 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg tilcotil (Ro12-0068) once daily for 2 weeks
Number of subjects: 8
Study 6342955 — intervention group
Group type: COMPARATOR
Intervention: 900 mg enteric-coated aspirin 4 times daily for 2 weeks
Number of subjects: 8
Study 31710306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Text messages (OHT)
Number of subjects: 55
Study 31710306 — intervention group
Group type: COMPARATOR
Intervention: Child Wellness Text messages (CWT)
Number of subjects: 55
Study 26607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic 0.9% sodium chloride
Number of subjects: 133
Study 26607495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic 3% sodium chloride
Number of subjects: 133
Study 26607495 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 133
Study 26607495 — intervention group
Group type: EXPERIMENTAL
Intervention: WARM respiratory distress score
Number of subjects: 133
Study 24785600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 121
Study 24785600 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgical resection
Number of subjects: 121
Study 22748729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention program
Number of subjects: 120
Study 22748729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 19486267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG-PSN injection (0.5 ml every other day for 2 weeks)
Number of subjects: 56
Study 19486267 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (10 mg every week for 2 weeks)
Number of subjects: 56
Study 19486267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional BCG-PSN injection
Number of subjects: 56
Study 19486267 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 56
Study 17300479 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for diabetes management
Number of subjects: 116
Study 17300479 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 116
Study 15149248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with nonassociated, neutral categories differing in salience
Number of subjects: 0
Study 15149248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with manipulated salience asymmetries while holding associations constant
Number of subjects: 0
Study 15149248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT) with manipulated valent associations while holding salience asymmetries constant
Number of subjects: 0
Study 15149248 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task to assess salience asymmetries
Number of subjects: 0
Study 11606340 — intervention group
Group type: EXPERIMENTAL
Intervention: IM droperidol 0.1 mg x kg(‐1) 30 min before anesthesia
Number of subjects: 23
Study 11606340 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 23
Study 9539198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (stress reduction)
Number of subjects: 60
Study 9539198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (energy intake reduction)
Number of subjects: 60
Study 9539198 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 60
Study 9116924 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 366
Study 9116924 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg titrated to 100 mg
Number of subjects: 366
Study 9116924 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 366
Study 2667265 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (ubiquinone) 3x 33.3 mg per day, orally for four months
Number of subjects: 25
Study 2667265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 598611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 41
Study 598611 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 41
Study 31825192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg)
Number of subjects: 184
Study 31048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low use alcohol, marijuana, and tobacco users (n = 244)
Number of subjects: 343
Study 31048112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol, tobacco and marijuana users (n = 74)
Number of subjects: 343
Study 31048112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk polysubstance users (n = 25)
Number of subjects: 343
Study 28925969 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg of body mass)
Number of subjects: 20
Study 24879357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4837
Study 24879357 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (2 g/day)
Number of subjects: 4837
Study 24879357 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA (400 mg/day)
Number of subjects: 4837
Study 24879357 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 4837
Study 24280596 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin plus ezetimibe 10 mg daily
Number of subjects: 286
Study 24280596 — intervention group
Group type: COMPARATOR
Intervention: Statin uptitration (double doses of statin)
Number of subjects: 286
Study 21989792 — intervention group
Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg daily
Number of subjects: 624
Study 21989792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 19445545 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (psychopharmacologic treatment combined with psychosocial interventions)
Number of subjects: 0
Study 19445545 — intervention group
Group type: COMPARATOR
Intervention: Psychopharmacology alone
Number of subjects: 0
Study 16803808 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counseling
Number of subjects: 240
Study 16803808 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education (control)
Number of subjects: 240
Study 14506491 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 35% soy protein and 30% vegetable protein
Number of subjects: 14
Study 14506491 — intervention group
Group type: COMPARATOR
Intervention: Usual nephropathy diet (0.8 g/kg protein, 70% animal and 30% vegetable protein)
Number of subjects: 14
Study 10981570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (160 microg in 4 ml normal saline)
Number of subjects: 24
Study 10981570 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal nalbuphine (400 microg in 4 ml normal saline)
Number of subjects: 24
Study 9277384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 6
Study 9277384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8310144 — intervention group
Group type: EXPERIMENTAL
Intervention: Beams‐Eye‐View designed customised blocks
Number of subjects: 0
Study 8310144 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy technique (implied control)
Number of subjects: 0
Study 3709028 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral and intravenous doses of bumetanide (CRF group)
Number of subjects: 10
Study 3709028 — intervention group
Group type: COMPARATOR
Intervention: 5 mg oral and intravenous doses of bumetanide (HS group)
Number of subjects: 10
Study 30092782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 364
Study 30092782 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion
Number of subjects: 364
Study 30092782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-to-potassium ratio
Number of subjects: 364
Study 30092782 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with potassium intake and sodium-to-potassium ratio
Number of subjects: 364
Study 26874868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal practices (IVPs)
Number of subjects: 529
Study 26874868 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting any sexually transmitted infection in the previous 6 months
Number of subjects: 529
Study 26874868 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more pregnancies
Number of subjects: 529
Study 26874868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients who became violent when proposing condom use
Number of subjects: 529
Study 24336090 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led daily 10-minute stress management intervention for 4 months
Number of subjects: 14
Study 24336090 — intervention group
Group type: COMPARATOR
Intervention: Control class (reading from a children's book for 10 minutes daily)
Number of subjects: 14
Study 22484082 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+P training
Number of subjects: 16
Study 22484082 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS+P training
Number of subjects: 16
Study 22484082 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RT+P and EMS+P
Number of subjects: 16
Study 20032491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (salmon)
Number of subjects: 161
Study 20032491 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (cod)
Number of subjects: 161
Study 20032491 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (DA)
Number of subjects: 161
Study 17658091 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI as a continuous variable
Number of subjects: 1814
Study 17658091 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpable tumors
Number of subjects: 1814
Study 17658091 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI classified as categorical variable
Number of subjects: 1814
Study 17658091 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 1814
Study 17658091 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 1814
Study 16055643 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Motivation to Respond Without Sexism (IMS‐S)
Number of subjects: 0
Study 16055643 — intervention group
Group type: EXPERIMENTAL
Intervention: External Motivation to Respond Without Sexism (EMS‐S)
Number of subjects: 0
Study 16055643 — intervention group
Group type: COMPARATOR
Intervention: Low Internal and External Motivation to Respond Without Sexism
Number of subjects: 0
Study 12145020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-containing formula
Number of subjects: 18
Study 12145020 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free formula
Number of subjects: 18
Study 9932590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nostril dilator
Number of subjects: 42
Study 8578810 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal vaccination of infants in their first year of life and adolescents at 12 years of age in Afragola
Number of subjects: 0
Study 8578810 — intervention group
Group type: COMPARATOR
Intervention: Selective vaccination of high risk groups in Frattamaggiore
Number of subjects: 0
Study 2093126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg) with Quinidine (100 mg)
Number of subjects: 16
Study 2093126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg) with Quinidine (200 mg)
Number of subjects: 16
Study 2093126 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone (group A)
Number of subjects: 16
Study 2093126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with Quinidine (group A)
Number of subjects: 16
Study 29719179 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg per day
Number of subjects: 1958
Study 29719179 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg per day
Number of subjects: 1958
Study 29719179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1958
Study 28947445 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered corneal graft (n=10)
Number of subjects: 15
Study 28947445 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane (n=5)
Number of subjects: 15
Study 25844493 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers (ER) program
Number of subjects: 270
Study 23481512 — intervention group
Group type: EXPERIMENTAL
Intervention: mEOC+P
Number of subjects: 200
Study 23481512 — intervention group
Group type: COMPARATOR
Intervention: EOC
Number of subjects: 200
Study 21680059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen (100% oxygen at 15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Number of subjects: 117
Study 21680059 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (15 L/minute by nonrebreather mask for 5 minutes before and during sedation)
Number of subjects: 117
Study 21680059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 117
Study 21680059 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 117
Study 19151051 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 25
Study 19151051 — intervention group
Group type: COMPARATOR
Intervention: Cuffed tracheal tube
Number of subjects: 25